Cost-effectiveness of hepatitis B vaccine in The Gambia
โ Scribed by Andrew J. Hall; Robert L. Roberston; Paolo E. Crivelli; Yamandow Lowe; Hazel Inskip; Sharon K. Snow; Hilton Whittle
- Publisher
- Elsevier Science
- Year
- 1993
- Tongue
- English
- Weight
- 524 KB
- Volume
- 87
- Category
- Article
- ISSN
- 0035-9203
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Hepatitis A virus (HAV) infection is a substantial risk for travellers from low endemic countries to high endemic destinations. Costs and effects of alternative options for prevention were compared using formal decision analysis. General indications for the optimal prevention of hepatit
Liver disease and liver cancer associated with childhood-acquired chronic hepatitis B are leading causes of death among adults in China. Despite expanded newborn hepatitis B vaccination programs, approximately 20% of children under age 5 years and 40% of children aged 5 to 19 years remain unprotecte
Our objective in this study was to determine the costeffectiveness of hepatitis A vaccination strategies in healthy adults in the United States. We constructed a decision model simulating costs and health consequences for otherwise healthy adults with respect to hepatitis A prevention. Three strateg
In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment. This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to th